TY - JOUR
T1 - Bone strength in primary hyperparathyroidism.
AU - Bilezikian, John P.
PY - 2003
Y1 - 2003
N2 - In primary hyperparathyroidism, as is the case for any metabolic bone disease like osteoporosis, bone strength is a function of many variables. In addition to bone density, considerations of bone size, microarchitecture, and dynamic variables related to the evolution of the disease are all likely to influence bone strength. With greater tools to investigate these points and with newly identified cohorts of this disease, some of whom are presenting with the earliest manifestations of abnormal parathyroid function, it is expected that fresh insights will emerge. Greater knowledge of the disease should help in understanding anabolic aspects of PTH when it is used as a treatment for osteoporosis.
AB - In primary hyperparathyroidism, as is the case for any metabolic bone disease like osteoporosis, bone strength is a function of many variables. In addition to bone density, considerations of bone size, microarchitecture, and dynamic variables related to the evolution of the disease are all likely to influence bone strength. With greater tools to investigate these points and with newly identified cohorts of this disease, some of whom are presenting with the earliest manifestations of abnormal parathyroid function, it is expected that fresh insights will emerge. Greater knowledge of the disease should help in understanding anabolic aspects of PTH when it is used as a treatment for osteoporosis.
UR - http://www.scopus.com/inward/record.url?scp=3242669697&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3242669697&partnerID=8YFLogxK
U2 - 10.1007/s00198-003-1482-4
DO - 10.1007/s00198-003-1482-4
M3 - Review article
C2 - 14504715
AN - SCOPUS:3242669697
SN - 0937-941X
VL - 14 Suppl 5
SP - S113-115; discussion S115-117
JO - Osteoporosis International
JF - Osteoporosis International
ER -